Allerberger et al
19
|
1979-1989 |
30 |
52.6 (3-81 years) |
3 |
S. typhimurium (n = 8, 26.7%),
S. Enteritidis (n = 5, 16.7%),
S. Agona (n = 3, 10%), S.
Blockley (n = 1, 3%), S. Bovismorbificans
(n = 1, 3%), S. Derby (n = 1, 3%),
S. Java (n = 1, 3%), S.
Manhattan (n = 1, 3%), S. Muenchen (n = 1, 3%),
S. Newport (n = 1, 3%), S.
Ohio (n = 1, 3%), S. Panama (n = 1, 3%),
S. Sandiego (n = 1, 3%),
S. Schwarzengrund (n = 1, 3%), Serotype not
investigated (n = 3, 10%) |
Significant underlying disease (n = 24, 80%), urologic
conditions (n = 23, 76.7%) |
Ramos et al
16
|
1978-1992 |
28 |
56 (22-82 years) |
Nil |
S. Enteritidis (n = 16, 57.1%),
S. Typhimurium (n = 5, 17.9%),
S. Derby (n = 2, 7.1%), S.
Blockley (n = 1, 3.6%), S. California (n = 1,
3.6%), S. Heidelberg (n = 1, 3.6%),
S. Ohio (n = 1, 3.6%), S.
Tilburg (n = 1, 3.6%) |
Severely immunocompromized (n = 17, 60.7%), urologic conditions
(n = 14, 50%) |
Paterson et al
12
|
1995-1996 |
23 |
35 (1-89) |
7 |
S. Birkenhead (n = 3, 13%), S.
Muenchen (n = 2, 8.7%), S. Virchow (n = 2,
8.7%), Others not stated explicitly |
None had organ transplant, HIV infection, immunosuppression.
Urologic conditions (n = 3, 13%) |
Tena et al
8
|
1990-2005 |
19 |
62.5 (3-92) |
2 |
S. Enteritidis (n = 16, 84.2%),
S. Typhimurium (n = 3, 15.8%) |
Diabetes Mellitus (n = 8, 42.1%), immunosuppressant treatment
(n = 7, 36.8%), urologic conditions (n = 8, 42.1%) |